Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of GR1803 in relapsed/refractory multiple myeloma
CTR20242576Phase 2Active
- Sponsor
- Zhixiang Jintai
- Start
- Aug 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of velinotamig in multiple myeloma (MM), sponsored by Zhixiang Jintai. Started Aug 2024; status: active.
02
Drugs
velinotamig
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20242576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242576.